GeoVax to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Wednesday, August 9, 2023
July 26 2023 - 8:00AM
via NewMediaWire
– GeoVax Labs, Inc. (Nasdaq: GOVX), a
clinical-stage biotechnology company developing immunotherapies and
vaccines against cancer and infectious diseases, announced today
that it will report second quarter 2023 financial results on
Wednesday, August 9, 2023, after the market closes.
Following the release, management will host a live conference
call and webcast to provide a general business update and discuss
financial results. Subsequent to management’s prepared remarks,
there will be a Q&A period for analysts and others.
Wednesday, August 9, 2023, 4:30 PM
ETDomestic:
800-715-9871International:
646-307-1963Conference ID:
5604173Webcast:
GeoVax
Earnings Webcast
A webcast replay of the call will be available for
three months via the same link as the live webcast approximately
two hours after the end of the call.
About GeoVaxGeoVax Labs, Inc. is a
clinical-stage biotechnology company developing novel therapies and
vaccines for solid tumor cancers and many of the world’s most
threatening infectious diseases. The company’s lead program in
oncology is a novel oncolytic solid tumor gene-directed therapy,
Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for
advanced head and neck cancers. GeoVax’s lead infectious disease
candidate is GEO-CM04S1, a next-generation COVID-19 vaccine
targeting high-risk immunocompromised patient populations.
Currently in three Phase 2 clinical trials, GEO-CM04S1 is being
evaluated as a primary vaccine for immunocompromised patients such
as those suffering from hematologic cancers and other patient
populations for whom the current authorized COVID-19 vaccines are
insufficient, and as a booster vaccine in patients with chronic
lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2
clinical trial evaluating the vaccine as a more robust, durable
COVID-19 booster among healthy patients who previously received the
mRNA vaccines. GeoVax has a leadership team who have driven
significant value creation across multiple life science companies
over the past several decades. For more information, visit our
website: www.geovax.com.
Investor Relations Contact:Rich CockrellCG
Capital404-736-3838govx@cg.capital
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From May 2024 to Jun 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jun 2023 to Jun 2024